According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...

Now, the fight against HIV/AIDS is not just about governments and global health organisations anymore; it is a deeply personal one. And it is all about the choices you make, the conversations you have ...

The challenge with curing the Human Immunodeficiency Virus (HIV) is that it tends to hide dormant in cells, evading the body’s natural immune system as well as some therapies. A new study uses novel ...

One in 10 clinics in SA — across 22 health districts in six provinces — could start to hand out a twice-a-year anti-HIV jab ...

If someone becomes infected with HIV and does not seek timely treatment, the infection gradually progresses through three stages. Each stage has different symptoms and risks. HIV AIDS: If a person ...

One in 10 clinics in South Africa will start to hand out a twice-a-year anti-HIV jab as early as February. The country’s medicines regulator, Sahpra, says it’s on track to announce its registration ...

NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 ...

One in 10 clinics in South Africa—across 22 health districts in six provinces—could start to hand out a twice-a-year anti-HIV jab as early as ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.